Memory disorders as a possible component of paraneoplastic neurological syndrome – immunologically determined dementias
Authors:
J. Reban; Z. Vrajová; E. Bůrková; L. Zajícová
Published in:
Geriatrie a Gerontologie 2017, 6, č. 3: 113-116
Category:
Review Article
Overview
In the late 1980's, considerable attention has been paid to the immune processes affecting cerebral structures and consequently even the function of these areas. Processes were not triggered by the direct growth of the tumour, or metastases, but by antibodies attacking the tumour, but at the same time these antibodies attack neural structures antigenically identical. Antibodies produced by the patient were defined as onconeural and the relevant syndromes as paraneoplastic neurological syndromes (PNS). These neurological syndromes typically present before the diagnosis of cancer. The result of these processes might affect also brain structures responsible for cognitive functions and behaviour. Diagnostic procedures are proposed. These immunologically mediated dementias might be also treated accordingly.
KEYWORDS:
cognitive impairment – onconeural antibodies – paraneoplastic antibodies – checkpoints inhibitors – immunotherapy of Alzheimer’s disease
Sources
1. Vyhnálek M, Bartoš A, Dostál V. Diagnostikujeme a léčíme demence správně a včas? Výsledky průzkumu ve světle nových doporučení. Psychiatrie pro praxi 2012; 13(1).
2. Štourač P, Kadaňka Z. Paraneoplastické neurologické syndromy – protilátkový profil a jeho typické varianty. Klinická onkologie 2000; 13: 5.
3. Štourač P, Ambler Z. Paraneoplastické neurologické syndromy – základní charakteristika, klasifikace, etiopatogeneze a diagnostika. Neurologie pro praxi 2013; 14(1).
4. Bayer A, Reban J. Alzheimer's Disease and Related Conditions. Medea Press 2004
5. McKeon A. Autoimmune Disorders of the Central Nervous Systém. Neurohospitalist 2013; 3(2): 53–64.
6. Ioanidis P, Karatocostas D. How Reversible are Reversible Dementias. European Neurological Review 2011: 6(4): 230–3.
7. Tales A, Jessen F, Butler CH. Diagnosing Subjective Cognitive Impairment: A Non-Dementia Related Context. Journal of Alzheimer’s Disease 2015. Suppl. 1.
8. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine 2016; 8: 595–608.
9. Takemura AF. Immunotherapy for Alzheimer's disease shows promise. Nature 19323, 2016.
10. Rosebloom MH, Smith S, Akdal G, Geshwind M. Immunologically Mediated Dementias. Cur Neurol Neurosci Rep 2009; 9(5): 359–367.
11. Sadeghian H, Vernino S. Progress in the management of paraneoplastic neurological disorders. Ther Adv Neurol Disord 2010; (1): 43–52.
12. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndroms: report of EFNS task force. Eur J Neurol 2011; 18(1); 19-e3.
13. Steinman L. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insight from paraneoplastic disease. Eur J Immunol 2014: 3201–3205.
14. Danna-Farber. What is a Checkpoint Inhibitor? Immune Checpoint Inhibitor Definition. Cancer Research 2015.
15. Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment of metastatic cancer. JAMA Neurol 2016; 6.
16. Baruch K, Deczkowska A, Resenzweig N. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer´s disease. Nat Med 2016: 135–7.
17. Almuhaideb A, Papathanasiou N, Boman J. F-FDG PET/CT Imaging in oncology. Ann Saudi 2011; 31(1): 3–13.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2017 Issue 3
Most read in this issue
- Should patients with dementia be allowed to drive?
- Fall prevention in hospitalised patients – intervention programmes
- Alois Alzheimer and Oskar Fischer – 110th anniversary of important publications on dementia
- Senior citizens in traffic – a topic to concern ourselves with?